The present study is designed to evaluate the hypothesis that the Angiotensin-Converting
Enzyme (ACE) inhibitor Ramipril improves vascular function and reduces markers of low-grade
chronic inflammation and oxidative stress in patients with Rheumatoid Arthritis.